The total return over the past 12 months is +144.81% vs. +16.94% for the S&P 500. So far it's up +82.66% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +144.81% | +46.69% | +20.32% | N/A | N/A | N/A |
| Total Return CAGR | +144.81% | +46.69% | +20.32% | N/A | N/A | N/A |
| Revenue CAGR | +100.27% | +37.54% | +42.66% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
UroGen Pharma Ltd. (URGN)
| Year | Start price | End price | URGN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $23.42 | $42.78 | +82.66% | +14.51% | +68.15% |
| 2025 | $10.65 | $23.42 | +119.91% | +17.72% | +102.19% |
| 2024 | $15.00 | $10.65 | (29.00%) | +24.89% | (53.89%) |
| 2023 | $8.87 | $15.00 | +69.11% | +26.19% | +42.92% |
| 2022 | $9.51 | $8.87 | (6.73%) | (18.17%) | +11.44% |
| 2021 | $18.02 | $9.51 | (47.23%) | +28.74% | (75.97%) |
| 2020 | $33.37 | $18.02 | (46.00%) | +18.37% | (64.37%) |
| 2019 | $43.06 | $33.37 | (22.50%) | +31.22% | (53.72%) |
| 2018 | $37.21 | $43.06 | +15.72% | (4.56%) | +20.28% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
